Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Часто задаваемые вопросы
В каком секторе работает Artiva Biotherapeutics, Inc. Common Stock (ARTV)?
Artiva Biotherapeutics, Inc. Common Stock относится к сектору Здравоохранение.
Какова текущая цена акций Artiva Biotherapeutics, Inc. Common Stock (ARTV)?
По последним данным, цена акций Artiva Biotherapeutics, Inc. Common Stock составляет 11,78 $, предыдущее закрытие — 11,22 $. За последнюю торговую сессию акции Artiva Biotherapeutics, Inc. Common Stock выросли на 0,56 $, что соответствует росту на 4,99%.
Выплачивает ли Artiva Biotherapeutics, Inc. Common Stock (ARTV) дивиденды?
Нет, Artiva Biotherapeutics, Inc. Common Stock не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Artiva Biotherapeutics, Inc. Common Stock (ARTV)?
У компании Artiva Biotherapeutics, Inc. Common Stock бета 2.177, что свидетельствует о крайне высокой волатильности по сравнению с рынком
